Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 6,239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Patient Level Clear all
Terminated Phase 1Phase 2 Interventional Results available

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT05405309
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
RP-3500, Olaparib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 27, 2026, 9:06 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Robotic Assisted Sacral Colpopexy : A Prospective Study Assessing Outcomes With Learning Curves

NCT01535833
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Device- Robotic sacral colpopexy
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Phase 1 Interventional

Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation

NCT04131738
View directory record Official record
Conditions
Graft-versus-host-disease, Graft Vs Host Disease
Interventions
Baricitinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 27, 2026, 9:06 PM EDT
Terminated Phase 3 Interventional

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

NCT00005113
View directory record Official record
Conditions
End-Stage Renal Disease, Kidney Transplantation
Interventions
Cyclosporine, Sirolimus, Tacrolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 20 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 27, 2026, 9:06 PM EDT
Recruiting Phase 1 Interventional

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

NCT04443088
View directory record Official record
Conditions
Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
Interventions
INV-1120, Pembrolizumab
Drug · Combination Product
Lead sponsor
Shenzhen Ionova Life Sciences Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Lafayette, Indiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 27, 2026, 9:06 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Robot-Assisted Stroke Rehabilitation Based on Patient-Therapist Interactions

NCT02806843
View directory record Official record
Conditions
Stroke, Hemiplegia, Healthy
Interventions
Rehab InterCap system and 3D Kinect
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 27, 2026, 9:06 PM EDT
Not listed No phase listed Observational

MARS MRI in Revision THA With a Ceramic Femoral Head and Titanium Sleeve

NCT05686915
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
MARS MRI, Titanium Labs, Cobalt Labs, Chromium Labs
Diagnostic Test
Lead sponsor
Colorado Joint Replacement
Other
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Phase 1 Interventional

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

NCT00963768
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JNJ 28431754, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 27, 2026, 9:06 PM EDT
Terminated Phase 4 Interventional Results available

A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy

NCT02058290
View directory record Official record
Conditions
Bowel Obstruction
Interventions
IV morphine sulfate or Sponsor-approved equivalent, EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Miami, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 27, 2026, 9:06 PM EDT
Active, not recruiting Not applicable Interventional

Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study

NCT05065840
View directory record Official record
Conditions
Human Papilloma Virus, Human Papilloma Virus Vaccine
Interventions
CDC 4 Pillars Program
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Albany, Georgia • Atlanta, Georgia • Lithonia, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 27, 2026, 9:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

NCT01483690
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
Interventions
Decitabine, Vorinostat, Vincristine, Dexamethasone, Mitoxantrone, Pegaspargase, Methotrexate
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

NCT00386425
View directory record Official record
Conditions
Severe Sepsis
Interventions
Drotrecogin alfa (activated)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2010 · Synced Oct 27, 2026, 9:06 PM EDT
Not listed Not applicable Interventional

INcreasing Statin Prescribing in HIV Behavioral Economics REsearch

NCT03687060
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Knowledge assessment, Education Intervention, Provider Feedback
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Commerce, California • Lancaster, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 27, 2026, 9:06 PM EDT
Completed No phase listed Observational

The Cxbladder Monitoring Study

NCT02700659
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Cxbladder
Other
Lead sponsor
Pacific Edge Limited
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Homewood, Alabama • New Britain, Connecticut • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 27, 2026, 9:06 PM EDT
Terminated Not applicable Interventional

A Novel Imaging Modality to Evaluate Radiation-Induced Uterine Injury

NCT06518174
View directory record Official record
Conditions
Uterine Injury
Interventions
MRI, SWE, and US evaluation
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 9:06 PM EDT
Terminated Phase 2 Interventional Results available

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

NCT00250718
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Cancer
Interventions
Vincristine, VP-16, Rituximab, Dexamethasone, Levofloxacin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 3, 2015 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Phase 1 Interventional

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

NCT05638620
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
Interventions
stellate ganglion block with 0.5% bupivacaine
Drug
Lead sponsor
Jonathann Kuo, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 27, 2026, 9:06 PM EDT
Not listed Not applicable Interventional

Impact of Time Restricted Eating on Patients With Coronary Artery Disease (CAD) Undergoing Cardiac Rehabilitation

NCT05014880
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ICR (Intensive Cardiac Rehabilitation), ICR x TRE (Intensive Cardiac Rehabilitation x Time-Restricted Eating)
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 27, 2026, 9:06 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Linking Novel Diagnostics With Data-Driven Clinical Decision Support in the Emergency Department

NCT05335135
View directory record Official record
Conditions
Inpatient Hospitalization, Intensive Care Unit Admission, Inpatient Mortality, Sepsis and Septic Shock
Interventions
TriageGO-MDW Clinical Decision Support, Usual Care
Other
Lead sponsor
Stocastic, LLC
Industry
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Phase 2 Interventional Results available

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

NCT00625820
View directory record Official record
Conditions
Kidney Disease, Albuminuria
Interventions
6R BH4, Vitamin C
Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Not applicable Interventional

External vs Internal-triggered Augmented-reality Visual Cues to Treat Freezing of Gait

NCT05608915
View directory record Official record
Conditions
Parkinson Disease, Gait Disorders, Neurologic, Parkinsonian Disorders, Movement Disorders, Gait, Unsteady, Gait, Festinating
Interventions
No Cue, Conventional Cue, Constant Cue, Patient hand-triggered, Patient eye-triggered, Examiner-triggered
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Phase 1 Interventional

Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery

NCT00433576
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Stage I Colon Cancer, Stage I Rectal Cancer, Stage II Colon Cancer, Stage II Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
Interventions
resveratrol, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 27, 2026, 9:06 PM EDT
Completed Not applicable Interventional Results available

Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19

NCT04871776
View directory record Official record
Conditions
Covid19, Vaccine Refusal
Interventions
Messaging informed by construal level theory, Usual Care
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
3,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 27, 2026, 9:06 PM EDT
Recruiting Phase 1 Interventional

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

NCT06613217
View directory record Official record
Conditions
Relapsed Adult AML
Interventions
zelenirstat
Drug
Lead sponsor
Pacylex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 27, 2026, 9:06 PM EDT